Top

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Published in:

Open Access 01-12-2021 | Multiple Sclerosis | Letter to the Editor

Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod

Authors: Gulnaz Siddiqui, Heidi Maloni, Victor E. Nava

Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery | Issue 1/2021

Excerpt

To the editor, …

Mansoor S, Kelly S, Murphy K, Waters A, Siddiqui NS. COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: "what the bleep do we know? Egypt J Neurol Psychiatry Neurosurg. 2020;56(1):44.CrossRef

Bigaut K, Kremer L, Fleury M, Lanotte L, Collongues N, de Seze J, et al. Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: a mirror of the response after SARS-CoV-2 infection. Rev Neurol (Paris). 2021;177:1237–40.CrossRef

Al Jumah M, Abulaban A, Aggad H, Al Bunyan R, AlKhawajah M, Al Malik Y, Almejally M, Alnajashi H, Alshamrani F, Bohlega S, Cupler EJ, ElBoghdady A, Makkawi S, Qureshi S, Shami S, et al. Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia. Mult Scler Relat Disord. 2021;51:102925.CrossRef

Ufer M, Shakeri-Nejad K, Gardin A, Su Z, Paule I, Marbury TC, Legangneux E, et al. Impact of siponimod on vaccination response in a randomized, placebo-controlled study. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e398.CrossRef

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D, Eller A, Grützner J, Boesler C, Rosenbaum C, Kühnle M, Luxemburger U, Kemmer-Brück A, Langer D, Bexon M, Bolte S, Karikó K, Palanche T, Fischer B, Schultz A, Shi P, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully I, Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer P, Jansen KU, Türeci Ö, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594–9.CrossRef

Title: Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod
Authors: Gulnaz Siddiqui
Heidi Maloni
Victor E. Nava
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Sclerosis
Siponimod
COVID-19 Vaccination
COVID-19
Vaccination
SARS-CoV-2
Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery / Issue 1/2021
Electronic ISSN: 1687-8329
DOI: https://doi.org/10.1186/s41983-021-00428-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Neurological manifestations and neuroimaging findings in patients with SARS-CoV2—a systematic review

Neurologic manifestations of COVID-19 infection in Asia: a systematic review

High leukotriene B4 serum levels increase risk of painful diabetic neuropathy among type 2 diabetes mellitus patients

Impact of body mass index on duplex parameters of cranial vessels among the Egyptian population

Comparison of knowledge, attitude, socioeconomic burden, and mental health disorders of COVID-19 pandemic between general population and health care workers in Egypt

Does the second ischemic stroke herald a higher proportional risk for cognitive and physical impairment than the first-ever one?